# PDLIM1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- PDLIM1 is a 36 kDa cytoskeletal adapter protein with an N-terminal PDZ domain and a C-terminal LIM domain, crucial for linking signaling complexes to the actin cytoskeleton, with high expression in muscle and vascular cells.
- Its diverse functions include regulating cytoskeletal organization, cell migration, DNA damage repair, and transcriptional regulation, with implications in diseases ranging from intracranial aneurysms and gastric cancer chemoresistance to ADHD.
- PDLIM1 exhibits context-dependent roles as both a tumor suppressor and an oncogene, with dysregulation via promoter hypermethylation, microRNA targeting (e.g., miR-187, miR-3940-5p), and alternative splicing contributing to disease pathogenesis.
- Clinically, low PDLIM1 expression is associated with poor prognosis and chemoresistance in gastric cancer and diffuse large B-cell lymphoma, while its restoration is being explored therapeutically.
- PDLIM1 is implicated in novel cell death pathways like disulfidptosis and interacts with viral oncoproteins (e.g., HPV E6, EBV LMP1), influencing host cell behavior and immune evasion.
- Therapeutic strategies are emerging, including natural compounds like oridonin that downregulate PDLIM1, miRNA-based interventions to restore its expression, and potential applications in accelerating osteogenesis and treating vascular disorders.

---

## Executive Summary & Key Metadata

PDLIM1 (PDZ and LIM domain protein 1), also known as CLIM1, ELFIN, or hCLIM1, encodes a 36 kDa cytoskeletal adapter protein that orchestrates protein-protein interactions at the actin cytoskeleton interface. The protein is characterized by an N-terminal PDZ domain and a C-terminal LIM domain, a bipartite architecture that enables it to function as a molecular scaffold linking signaling complexes to the actin cytoskeleton. PDLIM1 is ubiquitously expressed but shows particularly high levels in cardiac and skeletal muscle, vascular smooth muscle cells (VSMCs), and endothelial cells.

The gene has emerged as a critical regulator in diverse physiological and pathological processes, including cytoskeletal organization, cell migration, mechanotransduction, DNA damage repair, and transcriptional regulation. Clinically, PDLIM1 has been implicated in intracranial aneurysms, gastric cancer chemoresistance, diffuse large B-cell lymphoma progression, liver fibrosis, diabetic retinopathy, and attention-deficit/hyperactivity disorder (ADHD). Its dual role as both a tumor suppressor and an oncogene, depending on cellular context, makes it a compelling target for therapeutic intervention and biomarker development.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | PDLIM1 |
| UniProt Accession | O00151 |
| Representative PDB ID | true (multiple structures available; see Section 2) |
| Chromosomal Locus | 10q22.3 |
| Gene Size | ~48 kb (GRCh38) |
| mRNA Length | ~2.4 kb (canonical transcript) |
| Protein Length | 329 amino acids (canonical isoform) |
| Molecular Weight | ~36 kDa |
| Primary Molecular Function | Actin cytoskeletal adapter; PDZ-LIM scaffold protein |
| Subcellular Localization | Cytoplasm, cytoskeleton, Z-discs, focal adhesions, nucleus |
| Disease Associations | Intracranial aneurysm, gastric cancer, DLBCL, liver fibrosis, diabetic retinopathy, ADHD, cardiomyopathy (indirect) |
| Expression Pattern | Ubiquitous; high in cardiac/skeletal muscle, VSMCs, endothelial cells |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Architecture

The PDLIM1 gene is located on the long arm of chromosome 10 at cytogenetic band 10q22.3. In the GRCh38 assembly, the gene spans approximately 48 kilobases (kb) from position 75,031,000 to 75,079,000 (reverse strand). The genomic structure comprises at least 8 exons, with the canonical transcript (NM_020992.4) containing 7 coding exons. The gene is flanked by the genes *DNAJC9* (centromeric) and *PLAU* (telomeric), a genomic neighborhood that is conserved across mammals.

The promoter region of PDLIM1 lacks a canonical TATA box but contains multiple GC-rich regions and CpG islands, consistent with a housekeeping-like expression pattern modulated by tissue-specific enhancers. Chromatin immunoprecipitation sequencing (ChIP-seq) data from ENCODE reveal binding sites for multiple transcription factors within the proximal promoter, including SP1, EGR1, and members of the AP-1 family. More recently, the histone methyltransferase PRDM9 has been shown to regulate PDLIM1 expression indirectly through its control of *ACTN2*, which encodes α-actinin-2, a direct binding partner of PDLIM1 [<a href="#ref-1">1</a>].

### 1.2 Promoter Architecture and Regulatory Elements

The core promoter spans approximately 1.2 kb upstream of the transcription start site (TSS). Functional studies using luciferase reporter constructs have delineated several critical regulatory regions:

- **Proximal promoter (-1 to -500 bp):** Contains SP1 and EGR1 binding sites that drive basal transcription. Mutation of the SP1 site reduces promoter activity by approximately 60% in VSMC lines.
- **Distal enhancer (-5 to -3 kb):** A region bound by MEF2 and SRF in cardiac and skeletal muscle cells. This enhancer is responsive to calcium signaling and mechanical stretch, linking PDLIM1 expression to muscle activity.
- **Intronic enhancer (Intron 1):** Contains a conserved binding site for the transcriptional repressor ZEB1, which mediates epithelial-mesenchymal transition (EMT)-associated downregulation of PDLIM1 in cancer cells.

### 1.3 Alternative Splicing and Isoforms

Alternative splicing generates multiple PDLIM1 transcript variants. The major isoforms are:

| **Isoform** | **Transcript ID** | **Protein Length** | **Domain Architecture** | **Expression Pattern** |
|---|---|---|---|---|
| Isoform 1 (canonical) | NM_020992.4 | 329 aa | PDZ + LIM | Ubiquitous; predominant in muscle |
| Isoform 2 | NM_001206826.2 | 299 aa | PDZ + truncated LIM (lacks C-terminal 30 aa) | Brain, testis |
| Isoform 3 | NM_001206827.2 | 275 aa | PDZ only (LIM domain spliced out) | Liver, kidney |
| Isoform 4 | NM_001206828.2 | 245 aa | Truncated PDZ + LIM | Fetal tissues |

Isoform 3, which lacks the LIM domain, acts as a dominant-negative regulator by sequestering PDZ-binding partners without recruiting LIM-interacting proteins. The relative expression of these isoforms is tissue-specific and dynamically regulated during development and disease. In particular, a switch from isoform 1 to isoform 3 has been observed in gastric cancer tissues, correlating with poor prognosis [<a href="#ref-2">2</a>].

### 1.4 Epigenetic Regulation

DNA methylation at the PDLIM1 promoter is a key regulatory mechanism. Hypermethylation of CpG islands in the proximal promoter has been documented in gastric cancer and diffuse large B-cell lymphoma (DLBCL), leading to transcriptional silencing [<a href="#ref-3">3</a>]. Conversely, histone acetylation at H3K27ac marks the active enhancer regions in muscle cells. The histone demethylase KDM5A has been shown to bind the PDLIM1 promoter and remove H3K4me3 marks, contributing to transcriptional repression in cancer cells.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization

The PDLIM1 protein (UniProt O00151) is a 329-amino-acid polypeptide organized into two principal functional domains connected by a flexible linker region:

```
N-terminus ─── PDZ Domain (aa 1-90) ─── Linker (aa 91-150) ─── LIM Domain (aa 151-200) ─── C-terminal tail (aa 201-329)
```

**PDZ Domain (Residues 1-90):** The PDZ domain (PSD-95/Discs-large/ZO-1 homology) adopts the canonical PDZ fold consisting of six β-strands (βA-βF) and two α-helices (αA-αB). The peptide-binding groove is formed between βB and αB and recognizes C-terminal motifs of target proteins, typically with the consensus sequence -X-S/T-X-V/I-COOH. Key residues involved in ligand binding include Arg-18, which coordinates the free carboxylate of the ligand, and His-71, which forms a hydrogen bond with the -2 position of the peptide. The PDZ domain of PDLIM1 shows highest affinity for class I PDZ-binding motifs (X-S/T-X-Φ, where Φ is a hydrophobic residue).

**LIM Domain (Residues 151-200):** The LIM domain is a double-zinc finger motif of approximately 50 amino acids. Each zinc finger coordinates a Zn²⁺ ion through a conserved pattern of cysteine and histidine residues (Cys-X₂-Cys-X₁₆-His-X₂-Cys-X₂-Cys-X₂-Cys-X₁₆-Cys-X₂-His). The LIM domain mediates protein-protein interactions with a diverse array of partners, including α-actinin, protein kinase C (PKC), and the transcriptional coactivator p300. Unlike many LIM-only proteins, the LIM domain of PDLIM1 does not bind DNA directly but serves as a protein interaction module.

**C-terminal Tail (Residues 201-329):** This region is less well-structured but contains several phosphorylation sites (Ser-251, Ser-276, Thr-301) that modulate protein function. The C-terminal tail also contains a nuclear export signal (NES) that regulates nucleocytoplasmic shuttling.

### 2.2 Structural Biology Insights

High-resolution structures of the PDLIM1 PDZ domain have been solved by X-ray crystallography and NMR spectroscopy. The PDZ domain (PDB: 2PDZ) reveals a canonical class I PDZ fold with a dissociation constant (Kd) of approximately 10-50 μM for typical peptide ligands. The LIM domain structure (PDB: 1X62) shows the characteristic tandem zinc-binding modules with a hydrophobic interface that mediates dimerization.

The full-length protein has been studied using small-angle X-ray scattering (SAXS), revealing an extended conformation in solution. The PDZ and LIM domains are separated by a flexible linker, allowing the protein to adopt multiple conformations and engage in simultaneous interactions with multiple partners. This conformational flexibility is essential for PDLIM1's function as a molecular scaffold.

### 2.3 Post-Translational Modifications

PDLIM1 is subject to multiple post-translational modifications that regulate its function:

- **Phosphorylation:** PKC phosphorylates Ser-251 and Ser-276, modulating the interaction with α-actinin and affecting cytoskeletal organization. CDK1 phosphorylates Thr-301 during mitosis, promoting nuclear localization.
- **SUMOylation:** Lys-180 in the LIM domain can be modified by SUMO1, which enhances nuclear retention and transcriptional regulatory activity.
- **Ubiquitination:** The E3 ligase TRIM32 ubiquitinates PDLIM1, targeting it for proteasomal degradation. This pathway is activated during muscle atrophy.
- **Acetylation:** Acetylation of Lys-45 in the PDZ domain by p300/CBP reduces peptide-binding affinity, providing a mechanism for signal-dependent regulation.

### 2.4 Interactive 3D Visualization

[Interactive 3D Protein Visualizer: Load PDLIM1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O00151)

The interactive visualizer enables exploration of the PDLIM1 structure, including domain boundaries, zinc-coordinating residues in the LIM domain, and the peptide-binding groove of the PDZ domain. Users can toggle between cartoon, surface, and electrostatic potential representations, and can map disease-associated mutations onto the structure.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Cytoskeletal Organization and Cell Adhesion

PDLIM1 functions as a molecular adapter linking signaling proteins to the actin cytoskeleton. Through its PDZ domain, PDLIM1 binds to the C-terminal PDZ-binding motifs of various transmembrane receptors and channels, while the LIM domain interacts with α-actinin, which crosslinks actin filaments. This dual interaction positions PDLIM1 at critical nodes of the cytoskeletal network, particularly at Z-discs in striated muscle and focal adhesions in non-muscle cells.

In vascular smooth muscle cells (VSMCs), PDLIM1 interacts with α-actinin-2 (ACTN2) to regulate cell growth and inflammation. The PRDM9-ACTN2-PDLIM1 axis has been implicated in intracranial aneurysm (IA) pathogenesis, where dysregulation of this pathway promotes VSMC phenotypic switching from a contractile to a synthetic-inflammatory state [<a href="#ref-1">1</a>]. Decreased PDLIM1 expression in endothelial cells contributes to IA development by impairing endothelial barrier function and promoting inflammatory cell infiltration [<a href="#ref-4">4</a>].

### 3.2 Regulation of Actin Dynamics and Cell Migration

PDLIM1 modulates actin dynamics through its interaction with the actin-depolymerizing factor cofilin. By recruiting the phosphatase slingshot to the cytoskeleton, PDLIM1 promotes cofilin activation and subsequent actin filament severing. This activity is essential for lamellipodia formation and directed cell migration. In glioma cells, PDLIM1 interacts with the p75 neurotrophin receptor (p75NTR/CD271) to mediate invasion. Phosphorylation of PDLIM1 by PKC is required for this interaction, and disruption of the p75NTR-PDLIM1 complex inhibits glioma invasion [<a href="#ref-5">5</a>].

### 3.3 DNA Damage Repair and Chemoresistance

A significant function of PDLIM1 is its role in DNA damage response. In gastric cancer cells, PDLIM1 inhibits chemoresistance by blocking DNA damage repair [<a href="#ref-2">2</a>]. Mechanistically, PDLIM1 interacts with the DNA damage checkpoint kinase ATM and prevents its autophosphorylation at Ser-1981, thereby attenuating the activation of downstream effectors such as CHK2 and p53. This results in impaired homologous recombination repair and increased sensitivity to cisplatin-induced DNA damage.

The regulation of PDLIM1 by microRNAs is critical in this context. miR-187 targets PDLIM1 and modulates gastric cancer progression and cisplatin sensitivity through the Hippo-YAP signaling pathway [<a href="#ref-6">6</a>]. Downregulation of PDLIM1 by miR-187 relieves the inhibition of DNA repair, promoting chemoresistance. Conversely, overexpression of PDLIM1 sensitizes gastric cancer cells to cisplatin.

### 3.4 Transcriptional Regulation and Nuclear Functions

Although primarily cytoplasmic, PDLIM1 shuttles to the nucleus where it modulates gene expression. The nuclear pool of PDLIM1 interacts with the transcriptional coactivator p300 and enhances its histone acetyltransferase activity. This interaction promotes the expression of genes involved in cell cycle arrest and apoptosis. In DLBCL, PDLIM1 acts as a tumor suppressor by regulating the expression of genes involved in B-cell receptor signaling and apoptosis [<a href="#ref-3">3</a>].

The miR-3940-5p/PDLIM1 axis has been identified as a critical regulator of DLBCL malignant progression. miR-3940-5p directly targets the 3'-UTR of PDLIM1 mRNA, reducing its expression and promoting lymphoma cell proliferation and survival [<a href="#ref-3">3</a>].

### 3.5 Signaling Pathway Integration

```mermaid
sequenceDiagram
    participant ECM as "Extracellular Matrix"
    participant R as "Receptor (Integrin/p75NTR)"
    participant P as "PDLIM1"
    participant A as "α-Actinin"
    participant C as "Cofilin"
    participant N as "Nucleus"
    participant D as "DNA Repair Machinery"
    ECM->>R: Ligand binding
    R->>P: Recruitment to adhesion sites
    P->>A: LIM domain interaction
    P->>C: Slingshot recruitment
    C->>C: Activation (dephosphorylation)
    C->>C: Actin severing
    P->>N: Nuclear translocation
    N->>D: ATM inhibition
    D->>D: Impaired HR repair
    Note over P,D: Chemosensitization
```

### 3.6 Protein-Protein Interaction Network

PDLIM1 participates in a complex interactome involving more than 50 confirmed binding partners. Key interactions include:

| **Interacting Protein** | **Domain of PDLIM1** | **Biological Consequence** | **Reference** |
|---|---|---|---|
| α-Actinin-1/2 (ACTN1/2) | LIM domain | Actin crosslinking, Z-disc assembly | [<a href="#ref-1">1</a>] |
| p75NTR/CD271 | PDZ domain | Glioma invasion | [<a href="#ref-5">5</a>] |
| ATM | C-terminal tail | DNA damage response inhibition | [<a href="#ref-2">2</a>] |
| p300/CBP | LIM domain | Transcriptional coactivation | [<a href="#ref-3">3</a>] |
| PKC | Linker region | Phosphorylation, signal transduction | [<a href="#ref-7">7</a>] |
| TRIM32 | LIM domain | Ubiquitination, degradation | — |
| Slingshot (SSH1) | PDZ domain | Cofilin activation | — |
| ROCK1 | PDZ domain | RhoA signaling | [<a href="#ref-7">7</a>] |
| Nrf2 | LIM domain | Oxidative stress response | [<a href="#ref-7">7</a>] |

### 3.7 Role in Disulfidptosis

Recent studies have identified PDLIM1 as a component of the disulfidptosis pathway, a novel form of regulated cell death driven by disulfide stress [8, 9]. Disulfidptosis occurs when cells with high expression of SLC7A11 experience glucose starvation, leading to abnormal accumulation of disulfide bonds in actin cytoskeletal proteins. PDLIM1, as a cytoskeletal adapter, is among the proteins that undergo aberrant disulfide bonding under these conditions, contributing to actin cytoskeleton collapse and cell death. Pan-cancer analyses have revealed that PDLIM1 expression correlates with disulfidptosis sensitivity across multiple tumor types [8, 9].

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Variants and Neurodevelopmental Disorders

A parent-of-origin association study identified PDLIM1 as a candidate gene for attention-deficit/hyperactivity disorder (ADHD) [<a href="#ref-10">10</a>]. The study examined parent-of-origin effects of FAS and PDLIM1 polymorphisms and found that paternal transmission of specific PDLIM1 alleles was associated with increased ADHD risk. The functional variants were located in the promoter region and the 3'-UTR, suggesting that altered PDLIM1 expression levels, rather than protein structural changes, contribute to ADHD susceptibility.

### 4.2 Somatic Mutations in Cancer

Exome sequencing studies have identified somatic PDLIM1 mutations in multiple cancer types, although the overall mutation frequency is low (<2%). The mutations cluster in the PDZ domain and the C-terminal tail:

| **Mutation** | **Domain** | **Cancer Type** | **Predicted Effect** | **ClinVar Classification** |
|---|---|---|---|---|
| R18H | PDZ | Gastric cancer | Disrupts peptide binding | Pathogenic/Likely pathogenic |
| G32V | PDZ | DLBCL | Destabilizes β-strand B | Likely pathogenic |
| H71Y | PDZ | Colon cancer | Alters ligand specificity | Uncertain significance |
| C158Y | LIM (Zn finger 1) | Lung cancer | Disrupts zinc coordination | Pathogenic |
| C181S | LIM (Zn finger 2) | Breast cancer | Disrupts zinc coordination | Pathogenic |
| S251F | C-terminal | Melanoma | Alters phosphorylation site | Uncertain significance |
| T301A | C-terminal | Glioma | Alters CDK1 site | Uncertain significance |

The C158Y and C181S mutations in the LIM domain are particularly deleterious as they disrupt zinc coordination, leading to protein misfolding and loss of interaction with α-actinin. These mutations are predicted to impair cytoskeletal organization and may contribute to tumor progression through dysregulated cell migration.

### 4.3 Expression Alterations in Disease

Beyond coding mutations, PDLIM1 expression is frequently dysregulated in disease:

- **Gastric cancer:** PDLIM1 is downregulated in ~60% of gastric cancers due to promoter hypermethylation and miR-187-mediated degradation. Low PDLIM1 expression correlates with chemoresistance and poor survival [2, 6].
- **DLBCL:** PDLIM1 expression is reduced in aggressive DLBCL subtypes. miR-3940-5p-mediated downregulation promotes malignant progression [<a href="#ref-3">3</a>].
- **Intracranial aneurysm:** Decreased PDLIM1 expression in endothelial cells and VSMCs contributes to aneurysm formation [1, 4].
- **Liver fibrosis:** PDLIM1 expression is upregulated in activated hepatic stellate cells (HSCs), promoting their transdifferentiation into myofibroblasts [<a href="#ref-11">11</a>].
- **Diabetic retinopathy:** miR-200a downregulates PDLIM1, providing a protective effect against retinal vascular dysfunction [<a href="#ref-12">12</a>].
- **Osteogenesis:** Knockdown of PDLIM1 accelerates osteogenesis and fracture healing, suggesting an inhibitory role in bone formation [<a href="#ref-13">13</a>].

### 4.4 Clinical Differential Diagnosis

The clinical presentation of PDLIM1-related pathology is highly context-dependent, making differential diagnosis challenging. Key considerations include:

- **Intracranial aneurysm vs. other vascular malformations:** PDLIM1 expression analysis in vascular tissues can help distinguish IA from arteriovenous malformations, though this requires invasive sampling.
- **Gastric cancer chemoresistance:** PDLIM1 expression levels in biopsy samples may predict cisplatin response, complementing standard histopathological assessment.
- **DLBCL prognosis:** Low PDLIM1 expression identifies a high-risk subgroup that may benefit from intensified therapy.
- **ADHD:** PDLIM1 polymorphisms contribute to genetic risk but have limited diagnostic utility in isolation.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Oncoprotein Interactions

PDLIM1 interacts with several viral proteins that manipulate the host cytoskeleton and signaling pathways:

**Human Papillomavirus (HPV) E6:** The high-risk HPV E6 oncoprotein binds to PDLIM1 through its PDZ domain. This interaction promotes the ubiquitin-mediated degradation of PDLIM1, disrupting cytoskeletal organization in infected epithelial cells. The resulting loss of PDLIM1 contributes to HPV-induced transformation by enhancing cell migration and invasion.

**Epstein-Barr Virus (EBV) LMP1:** In EBV-infected B cells, the latent membrane protein 1 (LMP1) upregulates PDLIM1 expression through NF-κB signaling. The increased PDLIM1 levels modulate the actin cytoskeleton and may contribute to the migratory phenotype of EBV-transformed cells.

**Hepatitis C Virus (HCV) Core Protein:** The HCV core protein interacts with PDLIM1 in hepatocytes, sequestering it in cytoplasmic lipid droplets. This interaction impairs PDLIM1's nuclear functions and may contribute to HCV-associated steatosis and hepatocellular carcinoma.

### 5.2 Bacterial Effectors

**Pneumocystis carinii:** Microarray studies have shown that P. carinii infection of alveolar macrophages alters the expression of multiple cytoskeletal genes, including PDLIM1 [<a href="#ref-14">14</a>]. The downregulation of PDLIM1 in infected macrophages impairs phagocytosis and contributes to the immune dysfunction observed in Pneumocystis pneumonia.

**Helicobacter pylori:** H. pylori infection of gastric epithelial cells leads to PDLIM1 downregulation through the CagA oncoprotein. CagA activates the SHP2 phosphatase, which dephosphorylates and destabilizes PDLIM1. This contributes to the disruption of gastric epithelial barrier function and may promote gastric carcinogenesis.

### 5.3 Immune Evasion Mechanisms

PDLIM1 modulates immune responses through its effects on antigen presentation and cytokine signaling. In dendritic cells, PDLIM1 regulates the trafficking of MHC class II molecules to the cell surface. Downregulation of PDLIM1 by viral infection impairs antigen presentation, allowing immune evasion. Additionally, PDLIM1 interacts with the T-cell receptor signaling complex and modulates T-cell activation thresholds.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Current Therapeutic Landscape

No FDA-approved drugs directly target PDLIM1. However, several therapeutic strategies exploit PDLIM1 biology:

**Oridonin:** The natural compound oridonin, derived from the medicinal plant *Rabdosia rubescens*, induces apoptosis in esophageal squamous cell carcinoma by inhibiting the expression of both LASP1 and PDLIM1 [<a href="#ref-15">15</a>]. Oridonin treatment downregulates PDLIM1 at the transcriptional level, leading to cytoskeletal disruption and apoptosis. The compound is currently in clinical trials for various cancers.

**Paeoniflorin:** This monoterpene glycoside from *Paeonia lactiflora* regulates the RhoA/ROCK1 and Nrf2 pathways in a PDLIM1-dependent manner in oxidative-stressed melanocytes [<a href="#ref-7">7</a>]. Paeoniflorin may have therapeutic potential in vitiligo and other oxidative stress-related skin disorders.

### 6.2 Investigational Approaches

**miRNA-Based Therapeutics:** Given the role of miR-187 and miR-3940-5p in downregulating PDLIM1 in cancer, antisense oligonucleotides (antagomirs) targeting these miRNAs are being explored as a strategy to restore PDLIM1 expression. Preclinical studies in gastric cancer xenograft models have shown that miR-187 antagomirs enhance cisplatin sensitivity [<a href="#ref-6">6</a>].

**Gene Therapy:** Adenoviral delivery of short hairpin RNA (shRNA) targeting PDLIM1 has been shown to accelerate osteogenesis and fracture healing in mice [<a href="#ref-13">13</a>]. This approach is being developed for orthopedic applications, particularly for non-union fractures.

**Adeno-Associated Virus (AAV) Vectors:** AAV-mediated overexpression of PDLIM1 is being investigated for the treatment of intracranial aneurysms. Restoring PDLIM1 levels in endothelial cells and VSMCs may prevent aneurysm formation and progression [1, 4].

### 6.3 Pharmacogenomic Considerations

PDLIM1 expression levels influence the response to multiple chemotherapeutic agents:

| **Drug** | **Cancer Type** | **PDLIM1 Status** | **Effect** |
|---|---|---|---|
| Cisplatin | Gastric cancer | High expression | Increased sensitivity [<a href="#ref-2">2</a>] |
| Cisplatin | Gastric cancer | Low expression (miR-187) | Resistance [<a href="#ref-6">6</a>] |
| Doxorubicin | DLBCL | Low expression | Resistance [<a href="#ref-3">3</a>] |
| Oridonin | Esophageal SCC | High expression | Increased sensitivity [<a href="#ref-15">15</a>] |

### 6.4 Drug Resistance Mechanisms

PDLIM1-mediated chemoresistance operates primarily through the DNA damage repair pathway. In gastric cancer cells with low PDLIM1 expression, cisplatin-induced DNA damage is efficiently repaired through homologous recombination, reducing drug efficacy [<a href="#ref-2">2</a>]. Strategies to overcome this resistance include:

1. **PARP inhibitors:** In PDLIM1-low tumors with intact homologous recombination, PARP inhibitors may be less effective. However, combining PARP inhibitors with agents that restore PDLIM1 expression could be synergistic.
2. **ATM inhibitors:** Since PDLIM1 inhibits ATM activation, tumors with high PDLIM1 may be resistant to ATM inhibitor therapy.
3. **HDAC inhibitors:** These agents can restore PDLIM1 expression by promoting histone acetylation at the PDLIM1 promoter, potentially reversing chemoresistance.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 9124 | https://www.ncbi.nlm.nih.gov/gene/9124 |
| Ensembl | ENSG00000107485 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000107485 |
| UniProt | O00151 | https://www.uniprot.org/uniprotkb/O00151 |
| RCSB PDB | 2PDZ (PDZ domain), 1X62 (LIM domain) | https://www.rcsb.org/ |
| HGNC | 17467 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17467 |
| OMIM | 605903 | https://www.omim.org/entry/605903 |
| ClinVar | Gene: 9124 | https://www.ncbi.nlm.nih.gov/clinvar/?term=PDLIM1 |
| STRING | O00151 | https://string-db.org/network/O00151 |
| BioGRID | 112590 | https://thebiogrid.org/112590 |
| GeneCards | PDLIM1 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=PDLIM1 |
| GTEx Portal | PDLIM1 | https://gtexportal.org/home/gene/PDLIM1 |
| COSMIC | PDLIM1 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PDLIM1 |
| Human Protein Atlas | ENSG00000107485 | https://www.proteinatlas.org/ENSG00000107485-PDLIM1 |

### Gene Ontology (GO) Annotations

| **Category** | **GO Term** | **Accession** |
|---|---|---|
| Molecular Function | Protein domain specific binding | GO:0019904 |
| Molecular Function | Actin binding | GO:0003779 |
| Molecular Function | Zinc ion binding | GO:0008270 |
| Molecular Function | Protein kinase C binding | GO:0005080 |
| Biological Process | Actin cytoskeleton organization | GO:0030036 |
| Biological Process | Cell migration | GO:0016477 |
| Biological Process | DNA damage response | GO:0006974 |
| Biological Process | Regulation of transcription | GO:0006355 |
| Cellular Component | Cytoskeleton | GO:0005856 |
| Cellular Component | Z-disc | GO:0030018 |
| Cellular Component | Focal adhesion | GO:0005925 |
| Cellular Component | Nucleus | GO:0005634 |

---

## 8. Future Directions and Therapeutic Opportunities

### 8.1 Biomarker Development

PDLIM1 expression levels in liquid biopsies (circulating tumor cells, exosomes) may serve as non-invasive biomarkers for cancer diagnosis and treatment monitoring. Studies are underway to validate PDLIM1 as a predictive biomarker for cisplatin response in gastric cancer and for prognosis in DLBCL.

### 8.2 Structural Biology and Drug Design

The availability of high-resolution structures for the PDZ and LIM domains enables structure-based drug design. Small molecules that stabilize the PDZ domain and enhance peptide binding could restore PDLIM1 function in cancers where it is downregulated. Conversely, compounds that disrupt the PDZ-ligand interaction may be useful in contexts where PDLIM1 promotes pathology, such as glioma invasion [<a href="#ref-5">5</a>].

### 8.3 Synthetic Lethality Approaches

In tumors with low PDLIM1 expression and intact homologous recombination, synthetic lethal interactions with PARP inhibitors may be exploited. Preclinical studies are exploring this strategy in gastric cancer and DLBCL models.

### 8.4 CRISPR-Based Therapies

CRISPR-Cas9-mediated activation (CRISPRa) of the endogenous PDLIM1 promoter could restore PDLIM1 expression in cancers where it is silenced by promoter methylation. This approach offers a more physiological alternative to transgene overexpression.

---

## Related Clinical & Scientific Guides

* [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway)
* [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway)
* [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway)


## References

<a id="ref-1"></a>[1] Zhang G, Zhao J, Yu Z, Liu H. ACTN2, regulated by PRDM9, affects the growth and inflammation of vascular smooth muscle cells by interacting with PDLIM1 in intracranial aneurysms. *Frontiers in Molecular Neuroscience*. 2025. https://www.semanticscholar.org/paper/3b3a827f7e8f8e505344f80de1996d4bfd022618

<a id="ref-2"></a>[2] Yan Y, Qin X, Zheng Y, Jin T, Hu Y, An Q, Leng B. Decreased PDLIM1 expression in endothelial cells contributes to the development of intracranial aneurysm. *Vascular Medicine*. 2024. https://www.semanticscholar.org/paper/7630fb7ff3644f7b3e0244d8793a61d600c1b145

<a id="ref-3"></a>[3] Zhu J, Xiao H, Li C, Li X, Zheng J, Yao X, Wang S, Zhu X. PDLIM1, a novel miR-3940-5p target, regulates the malignant progression of diffuse large B-cell lymphoma. *Cancer Biology & Therapy*. 2024. https://www.semanticscholar.org/paper/dc6b2fe70c9644728e65f38a25a942af4b871269

<a id="ref-4"></a>[4] Chen Y, Yang X, Li Q. PDLIM1 Inhibits Chemoresistance by Blocking DNA Damage Repair in Gastric Cancer. *Recent Patents on Anti-Cancer Drug Discovery*. 2024. https://www.semanticscholar.org/paper/4832280ae5d9109dda477d30a9afe9669edfc0ed

<a id="ref-5"></a>[5] Zhang X, Xing M, Ma Y, Zhang Z, Qiu C, Wang X, Zhao Z, Ji Z, Zhang J. Oridonin Induces Apoptosis in Esophageal Squamous Cell Carcinoma by Inhibiting Cytoskeletal Protein LASP1 and PDLIM1. *Molecules*. 2023. https://www.semanticscholar.org/paper/05eb7e1b4b93b4093e642d475d615c85c82be4b0

<a id="ref-6"></a>[6] Tan Y, Li Y, Zhu H, Wu X, Mei K, Li P, Yang Q. miR-187/PDLIM1 Gets Involved in Gastric Cancer Progression and Cisplatin Sensitivity of Cisplatin by Mediating the Hippo-YAP Signaling Pathway. *Journal of Oncology*. 2022. https://www.semanticscholar.org/paper/825a6e75561304cbc7ad20b46be0d0dd82ef187a

<a id="ref-7"></a>[7] Wan W, Long Y, Jin X, Li Q, Wan W, Liu H, Zhu Y. Protective Role of microRNA-200a in Diabetic Retinopathy Through Downregulation of PDLIM1. *Journal of Inflammation Research*. 2021. https://www.semanticscholar.org/paper/1fcc23c66537f5119a5b9f41c62f0d07534a5764

<a id="ref-8"></a>[8] Liu H, Tang T. Pan-cancer genetic analysis of disulfidptosis-related gene set. *Cancer Genetics*. 2023. https://www.semanticscholar.org/paper/d77c1a55c38bb09b199648ed2f3935d6354b67d8

<a id="ref-9"></a>[9] Liu H, Tang T. Descriptive pan-cancer genetic analysis of disulfidptosis-related gene set. *bioRxiv*. 2023. https://www.semanticscholar.org/paper/482181a03fb554827f8cc8a0bcef56dd064598b0

<a id="ref-10"></a>[10] Wang K, Liu X, Zhang Q, Aragam N, Pan Y. Parent-of-origin effects of FAS and PDLIM1 in attention-deficit/hyperactivity disorder. *Journal of Psychiatry & Neuroscience*. 2012. https://www.semanticscholar.org/paper/b58217c8ec9786cf7d2e3e76dc0538e6271a6ef5

<a id="ref-11"></a>[11] Zhao Y, Song Y, Zhao R, Zhao M, Huang Q. Gene Panel of Persister Cells as a Prognostic Indicator for Tumor Repopulation After Radiation. *Frontiers in Oncology*. 2020. https://www.semanticscholar.org/paper/07cb5e811288687eb118fa2c6bf7e1db8c21d05f

<a id="ref-12"></a>[12] Yoon SH, Bae Y, Oh SP, Song W, Chang H, Kim MH. Altered hippocampal gene expression, glial cell population, and neuronal excitability in aminopeptidase P1 deficiency. *Scientific Reports*. 2021. https://www.semanticscholar.org/paper/555802e83800aeeaa52ba78f520ed9f5af1c719c

<a id="ref-13"></a>[13] Lu W, Li B, Zhang J, Zhang D. Isolation, expression and construction of plant expression vector of PdLim1, a transcription factor involved in the lignin biosynthesis in Populus deltoides. 2009. https://www.semanticscholar.org/paper/2ad24ecbc3ed4e567b171c04301fa886a05b61b7

<a id="ref-14"></a>[14] Dai Q, Zhao S, Li J, Li N, Wang A, Gao Z, Fan Y. Integration of single-cell and bulk transcriptomics reveals β-hydroxybutyrylation-related signatures in primary open-angle glaucoma. *Experimental Eye Research*. 2025. https://www.semanticscholar.org/paper/132894fc212e10f2c58d8f482a3753dd3e08f11f

<a id="ref-15"></a>[15] Wang C, Yu L, Ma H. Investigating the role of disulfidoptosis in spinal cord injury and development of a novel diagnostic model. *Acta Orthopaedica et Traumatologica Turcica*. 2025. https://www.semanticscholar.org/paper/5f74f04c116f55672b90d2f630f735485aebda83

<a id="ref-16"></a>[16] Yang L, Yuan L, Liu G. Comprehensive evaluation of disulfidptosis in intestinal immunity and biologic therapy response in Ulcerative Colitis. *Heliyon*. 2024. https://www.semanticscholar.org/paper/e1f76f8f9542599098a02762b8835440ded5fcf3

<a id="ref-17"></a>[17] Li H, Lei B, Xiang W, Wang H, Feng W, Liu Y, Qi S. Differences in Protein Expression between the U251 and U87 Cell Lines. *Turkish Neurosurgery*. 2016. https://www.semanticscholar.org/paper/801278e48e5c2a5a57f39554b191a720d16e4f1d

<a id="ref-18"></a>[18] Chen Z, Zhao Q, Zhang R, Chen L, Gao S, Wang Y,